Brain neuro-plasticity, depression, and antidepressant therapy
Abstract
Aim. To investigate tianeptine effects on depressive symptoms, physical performance, and quality of life (QoL) in patients with stable coronary heart disease (CHD).
Material and methods. The study included 40 patients (20 men and 20 women), aged 36-72 years, with Functional Class (FC) II-III effort angina and co-morbid depression. All participants were randomized into two groups: the control group (standard therapy only) and the main group (standard therapy plus tianeptine, 37,5 mg/d for 6 weeks). Depression was diagnosed by Beck Depression Inventory, BDI (≥19 points) and clinical depressive symptoms, according to ICD-10. Physical performance was assessed in a stress test (veloergometry), and QoL – by a QoL questionnaire (at baseline and at Day 42).
Results. Tianeptine demonstrated substantial anti-depressive effect: in the main group, the total BDI score decreased from 24,9±1,2 to 11,9±1,5 (-52%; р<0,001). Clinical status also improved: the number and severity of angina attacks decreased; in patients with co-morbid arterial hypertension, blood pressure (BP) control improved; the time of physical stress test increased by 3,3±0,9 minutes (р<0,05). Total QoL score significantly increased by 2,6±0,9 (р<0,01). In the control group, no significant dynamics of these parameters was observed.
Conclusion. In CHD patients with depression, tianeptine therapy (37,5 mg/d) demonstrated substantial anti-depressive effect, improved BP control, increased physical stress tolerability and improved QoL.
About the Authors
G. V. Pogosova
State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies
Russian Federation
Moscow
Russian Federation
Moscow
I. E. Koltunov
State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies
Russian Federation
Moscow
Russian Federation
Moscow
Yu. M. Yufereva
State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies
Russian Federation
Moscow
Russian Federation
Moscow
A. K. Ausheva
State Research Centre for Preventive Medicine, Federal Agency on High Medical Technologies
Russian Federation
Moscow
Russian Federation
Moscow
References
1. Изнак А.Ф. Нейрональная пластичность и терапия аффективных расстройств. Психиатрия и психофармтерапия 2003; 5: 5.
2. Смулевич А.Б. Депрессии при соматических и психических заболеваниях. Москва 2003.
3. Ronald S. Duman. Structural alteration in depression: cellular mechanisms underlying pathology and treatment of mood disorders. CNS Spectrums 2002; 7: 140-7.
4. McEwen B.S., Magarinos A.M., Reagan L.P. Structural plastticity and tianeptine: cellular and molecular targets. Eur Psychiatry 2002; 17(3): 318-30.
5. Sheline Y.I., Mittler B.L., Mintun M.A. The hippocampus and depression. Eur Psychiatry 2002; 17(3): 300-5.
6. Magarinos A.M., Deslandes A., McEwen B.S. Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress. Eur J Pharmacol 1999; 371: 113-22.
7. Magarinos A.M., McEwen B.S. Experimental diabetes in rats causes hippocampal dendritic and synaptic reorganization and increased glucocorticoid reactivity to stress. Proc Natl Acad Sci USA 2000; 97: 11056-61.
8. Magarinos A.M., McEwen B.S., Flugge G. et al. Chronic psychosocial stress causes apical dendritic atrophy of hippocampal CA3 pyramidal neurons in subordinate tree shrews. J Neurosci 1996; 16: 3534-40.
9. Fuchs E., Czeh B., Michaelis T. et al. Alterations of neuroplasticity in depression: the hippocampus and beyond. (НВ)
10. Frodl T., Meisenzahl E.M., Zeitzsche T. еt al. Hippocampal changes in patients with a first episode of major depression. Am J Psychiatry 2002; 159: 1112-8.
11. Sheline Y.I., Sanghavi M., Mintun M. Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. J Neurosci 1999; 19(12): 5034-43.
12. Duman R.S. Pathophesiology of depression: the concept of synaptic plasticity. Eur Psychiatry 2002; 17(3): 306-10.
13. Fuchs E., Czeh B., Michaelis T. et al. Synaptic plasticity and tianeptine: structural regulation. Eur Psychiatry 2002; 17(3): 311-7.
14. Dsa C., Duman R.S. Antidepressants and neuroplasticity. Bipolar disorders 2002; 4: 183-94.
15. Ongur D., Dreveis W.C., Price J.L. Glial reduction in the sudgenial prefrontal cortex in mood disorders. Proc Natl Acad Sci USA 1998; 95: 13290-5.
16. Lucassen P., Fuchs E., Czeh B. Antidepressant treatment with tianeptine reduces in the hippocampal dentate gyrus and temporal cortex. Biol Psychiatry 2004; 55: 789-96.
17. Cameron H., McKay R.D.G. Adult neurogenesis produces a large pool of new granule cells in the dentate gyrus. J Comp Neurol 2001; 435: 406-17.
18. Niederhofer H. Therapy resistant major depression: improvement of symptomatology after combining antidepressants with Tianeptine (Stablon). Psychiatr. Prax. 2003;30(4): 221-2.
19. Смулевич А.Б. Сыркин А.Л. Психокардиология. 2005; 555-6.
20. Погосова Г.В. Депрессия – новый фактор риска ишемической болезни сердца и предиктор коронарной смерти. Кардиология 2002;4:86-91.
21. Дробижев М.Ю., Лебедева О.И., Добровольский А.В. Опыт применения тианептина при лечении тревожных депрессий у больных ишемической болезнью сердца. Тревога и обсессии. М 1998; 269-78.
22. Delbende C., Tranchand B.D., Tarozzo G et al. Effect of chronic treatment with the antidepressant tianeptine on the hypothalamo-pituitary-adrenal axis. Eur J Pharmacol 1994;251:245-51.
Review
For citations:
Pogosova G.V., Koltunov I.E., Yufereva Yu.M., Ausheva A.K. Brain neuro-plasticity, depression, and antidepressant therapy. Cardiovascular Therapy and Prevention. 2009;8(7):73-76. (In Russ.)
Views:
771
Email this article 
